Global Antivirals Market

2010-2025

Product Code VIS00068
Publication Date February 2010
Publisher Visiongain
Product Type Report
Pages 149
ISBN Number not applicable
Change currency
PDF £1,499.00 €1,805 $2,370 BUY >
Order by fax
Ask a question about this product > Receive product alerts > Call now +44 20 7060 7474

Global Antivirals Market

2010-2025

New report explains how this important anti-infective market will develop

In 2009, the global market for antiviral drugs attained total sales of over $28bn. With hundreds of millions of people worldwide suffering from chronic or acute viral infections, there is enormous need for antiviral drugs. It is only in the past few decades that researchers have begun to find ways of combating viruses. Because viruses mutate rapidly and acquire drug-resistance, the antiviral pipeline needs to be continuously replenished with newer, better therapies, our new market study notes.

Global Antivirals Market 2010-2025 forecasts how the global antivirals market will grow and change over the next 15 years. We predict that the market will continue to expand, driven by significant unmet needs, expanding patient populations, better diagnostics and innovative new drugs, including combination therapies. This report offers detailed and extensive coverage of the principal antiviral drugs, with comprehensive sales forecasting at class and brand levels. We also provide up-to-date assessments of the most-exciting antiviral agents in development.

This new study provides a detailed breakdown of the market by disease area, and forecasts how market shares of the main viral therapy classes will shift from 2010 onwards. More-effective and better-tolerated drugs will bring improved therapies for important diseases, including hepatitis B and C, to many patients in future. How will the global antiviral drug market develop from 2010 onwards? Where will the main revenue gains be made, by market sector and country? What are the most-promising R&D pipeline developments? This new report provides the answers that you require.

Global Antivirals Market 2010-2025 also assesses the leading companies, with their performances in the antivirals market predicted. We cover the leading national markets for antiviral agents separately, with comprehensive forecasts for North America, Europe and Asia. In particular, we examine China and India as expanding antiviral markets with large under-met patient needs at present.

Comprehensive analysis of the antiviral pharmaceuticals market

Global Antivirals Market 2010-2025 critically examines that sector through a comprehensive review of primary and secondary information sources. Our new report provides detailed sales forecasts, market share analyses, discussions of pipeline developments and analyses of commercial drivers and restraints. There are over 75 tables and figures included, as well as two original interviews with relevant experts. The result is a comprehensive market- and industry-centred study, with detailed analyses and informed opinion to benefit your work.

Why you should buy Global Antivirals Market 2010-2025

This report gives you the following benefits in particular:

  • You will receive a comprehensive analysis of the prospects for antiviral drugs from 2010 to 2025, including predicted revenues, growth rates and other important data
  • You will find out where the market is heading - both technologically and commercially - from the present onwards, both for the overall world market and for leading national markets
  • You will discover the prospects for leading companies and disease classes, including sales revenues and market shares from 2010 onwards
  • You will discover expert opinion from our original survey
  • You will identify key R&D pipeline developments and up-and-coming products
  • You will discover the drivers, restraints, competition and opportunities influencing the antivirals market
  • You will discover prospects for Tamiflu, in light of the recent swine flu outbreak.

Our research shows that new antiviral drugs have strong potential for commercial success if they are well-tolerated and more effective than existing products. The commercial potential and therapeutic expectations are high for R&D pipeline agents, with rapid technological advances.

You can obtain this report today

Nobody with an interest in the antiviral drug sector should overlook this new study. We predict that total revenues will increase over our forecast period, 2010 to 2025. With rising demand for products worldwide and current unmet needs, this market holds significant potential for further revenue growth and technological innovation. Do you want to harness those opportunities? You can stay ahead by ordering this report today.

Contents

  • 1. Executive Summary
    • 1.1 Aims and Methods of this Report
    • 1.2 Synopsis of Report
  • 2. Introduction
    • 2.1 What is a Virus?
    • 2.2 Viruses and Disease
    • 2.3 History of Virology
      • 2.3.1 Origin of Viruses
      • 2.3.2 Historical Developments in Virology
    • 2.4 Know Your Enemy: Classifying Viruses
      • 2.4.1 DNA Viruses
      • 2.4.2 RNA Viruses
      • 2.4.3. Reverse Transcribing Viruses
    • 2.5 Introducing Antiviral Drugs
      • 2.5.1. Antivirals Versus Vaccines
    • 2.6 The Viral Life Cycle and How to Stop It
      • 2.6.1 Cell Entry
      • 2.6.2 Viral Particles Synthesis
      • 2.6.3 Maturation and Release
      • 2.6.4 Immune System Modulating
    • 2.7 Antivirals Battle Highly Mutational Viral Genomes
    • 2.8 The Antiviral Class in the World Anti-Infective Market
  • 3. The Global Market for Antiviral Drugs, 2010-2025
    • 3.1 The Global Antiviral Market was Worth Over $28bn in 2009
    • 3.2 The Major Targets for Antiviral Drugs
      • 3.2.1 HIV Dominates the Market
      • 3.2.2 Hepatitis, Influenza and Herpes Markets
    • 3.3 The Main Methods of Targeting Viruses
      • 3.3.1 Reverse Transcriptase Inhibitors
      • 3.3.2 Protease Inhibitors
      • 3.3.3 Newer Anti-HIV Drug Classes
      • 3.3.4 Nucleoside Analogues
      • 3.3.5 Neuraminidase Inhibitors
      • 3.3.6 Immunoglobulin
    • 3.4 Global Antiviral Forecast 2010-2025
    • 3.5 Global Antiviral Market by Disease Area, 2010-2025
    • 3.6 The Rise of the Hepatitis Class from 2010-2025
      • 3.6.1 Hepatitis' Unique Market Strengths
    • 3.7 Trouble in the HIV Market
      • 3.7.1 Patent Expiry
      • 3.7.2 Problems with Developing World Markets
        • 3.7.2.1 Low Purchasing Power in Many African Countries
        • 3.7.2.2 Conflicts with Governments
        • 3.7.2.3 Premature Generics
        • 3.7.2.4 Compromise is Unavoidable in the Developing World
      • 3.7.3 The Outlook for The HIV Market
    • 3.8 Influenza and Patent Rights
      • 3.8.1 Pandemic Protection
      • 3.8.2 Generics Will Meet the Market Need
    • 3.9 Forecast for the Leading Antiviral Brands, 2010-2025
      • 3.9.1. Will Tamiflu Retain its Leadership Position?
      • 3.9.2 The Global Antivirals Market will Undergo Major Power Shift by 2015
      • 3.9.3 Commercial Future Lies in Combination Therapies
      • 3.9.4 Decline of the Pegasys-Ribavirin Combination Therapy?
      • 3.9.5 Atripla will Dominate the Antivirals Market
    • 3.10 Growing Investment in the Antivirals Market
  • 4. Factors Affecting the World Antiviral Market 2010-2025
    • 4.1 Strengths
      • 4.1.1 Resistance is Useful to the Market
      • 4.1.2 Chronic and Acute Indications Ensure Long-Term Demand for Antivirals
      • 4.1.3 Global Scope of the VIral Threat to Public Health
      • 4.1.4 Joint Public and Private Efforts to Facilitate Greater Accessibility are a Positive Step
    • 4.2 Weaknesses
      • 4.2.1 Demography
        • 4.2.1.1 Discounting Drugs for the Developing World
      • 4.2.2 High Drug Toxicity, Low Patient Compliance
      • 4.2.3 The Cost of Antiviral Treatments Forces Market Exclusivity and Limits Market Growth
      • 4.2.4. The Low Prevalence of Treatable Viral Diseases
    • 4.3 Opportunities
      • 4.3.1 Diagnostic Improvements
        • 4.3.1.1 The Advantages of Early Diagnosis
        • 4.3.1.2 The Majority of Patients Did Not Know They Were Infected
      • 4.3.2 Novel Targets and Mechanisms Constitute an Important Market Driver
    • 4.4 Threats
      • 4.4.1 Generic Penetration Threatens Leading Brands
      • 4.4.2 Does the R&D Pipeline Have Enough Potential to Replace the Ageing Brands?
      • 4.4.3. Problems with Patents
      • 4.4.4 Production Rate Unable to Meet Demand
      • 4.4.5 Vaccines - a Commercial Threat to Antiviral Drugs?
        • 4.4.5.1 What Will Happen?
    • 5. Leading Companies and Brands in the Antivirals Market, Forecast and Analysis 2010-2025
      • 5.1 The Big Three: GlaxoSmithKline, Gilead Sciences and Roche Dominate the Antivirals Market
      • 5.2 How Long Will GSK Stay on Top?
        • 5.2.1 GSK's Antiviral Drug Portfolio: Herpes and Influenza
        • 5.2.2 GSK and the HIV Market
      • 5.3 Gilead Sciences Carves into the HIV Market
      • 5.4 Roche and Biotechnology
      • 5.5 The Top 15 Antiviral Drugs of 2009
      • 5.6 Tamiflu (Roche)
        • 5.6.1 Tamiflu Dominates the Influenza Market
        • 5.6.2 Tamiflu's Market Performance Heavily Affected by Swine Flu
      • 5.7 Truvada (Gilead) - Market Prospects
      • 5.8 Atripla (Gilead) - Market Prospects
        • 5.8.1 Atripla Poised for HIV Market Hegemony?
        • 5.8.2. Potential Threats for Atripla
      • 5.9 Valtrex (GlaxoSmithKline) - Market Prospects
      • 5.10 Pegasys (Roche) - Market Prospects
      • 5.11 Reyataz (Bristol-Myers-Squibb) - Market Prospects
      • 5.12 Kaletra (Abbott) - Market Prospects
      • 5.13 Synagis (MedImmune/AstraZeneca) - Market Prospects
      • 5.14 Relenza (GlaxoSmithKline) - Market Prospects
      • 5.15 Epzicom (GlaxoSmithKline) - Market Prospects
      • 5.16 Pegintron (Schering-Plough) - Market Prospects
      • 5.17 Baraclude (Bristol-Myers-Squibb) - Market Prospects
      • 5.18 Prezista (Johnson & Johnson) - Market Prospects
      • 5.19 Combivir (GlaxoSmithKline - Market Prospects
      • 5.20 Isentress (Merck & Co) - Market Prospects
    • 6. Antivirals in the Leading Pharmaceutical Markets 2010-2025
      • 6.1 Sales of Antivirals in the Leading Pharmaceutical Markets in 2009
      • 6.2 Performance of Antivirals in the Leading National Markets, 2010-2025
      • 6.3 The US Dominance of the Antivirals Market
      • 6.4 Other Industrialised Country Markets to Achieve Steady Growth
      • 6.5 How Will the Leading Developing Countries Fare in the Global Antivirals Market?
        • 6.5.1 Relevant Healthcare Issues in China and India
    • 7. Antivirals Technology: The Future
      • 7.1 HIV Targets and Candidates
      • 7.2 New Reverse Transcriptase Inhibitors
        • 7.2.1 NRTI: Apricitabine (Shire)
        • 7.2.2 NNRTI: Rilipivirine (Johnson & Johnson; Tibotec-Virco)
      • 7.3 Integrase Inhibitors
        • 7.3.1 Elvitegravir (Gilead)
        • 7.3.2 The Quad Pill (Gilead)
        • 7.3.3 Other Integrase Inhibitors
      • 7.4 Entry Inhibitors
        • 7.4.1 The Potential Advantages of Host Targeting
        • 7.4.2 Stopping Viral Entry: Attachment, Entry and Fusion Inhibitors
        • 7.4.3 Vicrivoc (Schering-Plough)
      • 7.5 Maturation Inhibitors
        • 7.5.1 Bevirimat (Myriad)
      • 7.6 Other HIV Pipeline Products
      • 7.7 Hepatitis Pipeline Development
      • 7.8 Interferons and Other Immunomodulators
        • 7.8.1 Albuferon (Novartis; Human Genome Sciences)
      • 7.9 Protease Inhibitors for Hepatitis C
        • 7.9.1 Telaprevir (Vertex; Johnson & Johnson; Mitsubishi)
        • 7.9.2 Boceprevir (Schering-Plough)
      • 7.10 Polymerase Inhibitors
        • 7.10.1 R7128 (Roche; Pharmassett)
      • 7.11 New Frontiers in Antivirals
        • 7.11.1 Can Monoclonal Antibodies Compete with Small Molecules?
        • 7.11.2 Advantages of Monoclonal Antibodies
        • 7.11.3 RNA Interference Technology Raises Fervent Investment Interest
        • 7.11.4 Some RNA Interference Pipeline Products
    • 8. Interviews with Experts
      • 8.1 Interview 1: Professor Raymond F. Schinazi, Francis Winship Walters Professor of Pediatrics and Chemistry and Director of the Laboratory of Biochemical Pharmacology, Emory University and VA Medical Center
        • 8.1.1 On the Importance of Hepatitis C in the Next Decade
        • 8.1.2 On the New Treatments for Hepatitis C
        • 8.1.3 On the Challenge of Viral Mutation
        • 8.1.4 On HIV Treatment in the Next Decade
        • 8.1.5 On the Failure of Vaccines
        • 8.1.6 On the Cost of Antivirals
        • 8.1.7 On the Main Drivers of the Antivirals Market
        • 8.1.8 On Influenza Treatments
        • 8.1.9 On Host Targeting
      • 8.2 Interview 2: Dr. Michael Kinch, Vice President, Research and Development, Functional Genetics, Maryland, USA
        • 8.2.1 On Promising Sub-Markets
      • 8.2.2 On Market Drivers and Restraints
        • 8.2.3 On the Arguments for a Host-Oriented Therapeutic Approach
        • 8.2.4 On the Potential of Biologicals
    • 9. Conclusions
      • 9.1 The Antivirals Market Set to Grow
      • 9.2 The Next Market Leader
      • 9.3 The Rise of the Hepatitis Segment
      • 9.4 Pipeline Developments
      • 9.5 Antivirals: Summing up the Market's Prospects
    • List of Tables
      • Table 2.1, Major Events in History of Virology
      • Table 2.2, Classification of Clinically-Significant Viruses
      • Table 2.3, The Viral Life Cycle and Antiviral Drugs
      • Table 2.4, The World Anti-Infectives Market: Sales ($bn), 2009
      • Table 3.1, Blockbuster Antiviral Drugs: Sales ($m) and Market Shares (%), 2009
      • Table 3.2, Significant NRTIs and NNRTIs, 2010
      • Table 3.3, Global Antivirals Market: Sales ($bn), and Growth (%), 2009-2015, 2020, 2025
      • Table 3.4, Global Antivirals Market by Disease Area, 2009
      • Table 3.5, Global Antivirals Market Disease Areas: Sales ($bn), Growth (%), 2009-2015
      • Table 3.6, Market Performance of Hepatitis Segment: Sales ($bn), Growth Rate (%), CAGR (%), Market Shares (%), 2009-2015
      • Table 3.7, Top Marketed Antiviral Therapies: Sales ($bn) and Patent Expiry Dates, 2009
      • Table 3.8, Market Performance of HIV Segment: Sales ($bn), Growth Rate (%), CAGR (%), Market Shares (%), 2009-2015
      • Table 3.9, Market Performance of Influenza Segment: Sales ($bn), Growth Rate (%), CAGR (%), Market Shares (%), 2009-2015
      • Table 3.10, Top 15 Antiviral Brands: Sales ($m) and Growth (%), 2009
      • Table 4.1, SWOT Analysis of the Antivirals Market, 2010
      • Table 5.1, Leading Companies in the Antivirals Market: Sales ($bn), Market Shares (%), 2009
      • Table 5.2, Tamiflu Sales ($m), 2009-2025
      • Table 5.3, Truvada Sales ($m), 2009-2025
      • Table 5.4, Atripla Sales ($m), 2009-2015
      • Table 5.5, Valtrex Sales ($m), 2009-2025
      • Table 5.6, Pegasys Sales ($m), 2009-2025
      • Table 5.7, Reyataz Sales ($m), 2009-2025
      • Table 5.8, Leading Protease Inhibitors: Sales ($m), 2009-2025
      • Table 5.9, Kaletra Sales ($m), 2009-2025
      • Table 5.10, Synagis Sales ($m), 2009-2025
      • Table 5.11, Relenza Sales ($m), 2009-2025
      • Table 5.12, Epzicom Sales ($m), 2009-2025
      • Table 5.13, Pegintron Sales ($m), 2009-2025
      • Table 5.14, Baraclude Sales ($m), 2009-2025
      • Table 5.15, Prezista Sales ($m), 2009-2025
      • Table 5.16, Combivir Sales ($m), 2009-2025
      • Table 5.17, Isentress Sales ($m), 2009-2025
      • Table 6.1, Antivirals in the Leading Pharmaceuticals Markets: Sales ($m), Market Shares (%), Growth (%), 2009
      • Table 6.2, Antivirals in the Leading Pharmaceutical Markets: Sales ($m), 2009-2015, 2020, 2025
      • Table 6.3, Antivirals in the Leading Pharmaceutical Markets: Sales ($m), Market Shares (%) and CAGR (%), 2009 and 2015
      • Table 6.4, Number of HIV Patients in Key Countries, 2010
      • Table 7.1, HIV Life Cycle and Relevant Drug Classes, 2010
      • Table 7.2, NNRTIs Currently in Development, 2010
      • Table 7.3, Selected Products for HIV Treatment in Phase II Development, 2010
      • Table 7.4, Selected Products for Hepatitis C Treatment in Phase II Development, 2010
      • Table 9.1, Global Antivirals Market: Sales ($bn), 2009-2025
    • List of Figures
      • Figure 2.1, The World Anti-Infectives Market: Sales ($m), 2009
      • Figure 3.1, Leading Disease Areas in the Antivirals Market: Sales ($m), 2009
      • Figure 3.2, Leading Drug Classes in the Antivirals Market: Sales ($bn), 2009
      • Figure 3.3, Drug Classes: Market Shares (%), 2009
      • Figure 3.4, Drug Classes in the HIV Disease Area: Sales ($bn), 2009
      • Figure 3.5, Global Antivirals Market: Sales ($bn), 2009-2015
      • Figure 3.6, Global Antivirals Market by Disease Area: Sales ($bn), Market Shares (%), 2009
      • Figure 3.7, Global Antivirals Market by Disease Area: Sales ($bn), 2009-2015
      • Figure 3.8, Global Hepatitis Market: Sales ($bn), 2009-2025
      • Figure 3.9, Global HIV Market: Sales ($bn), 2009-2015
      • Figure 3.10, Global Influenza Market: Sales ($bn), 2009-2015
      • Figure 3.11, Market Shares (%) of the Leading Antiviral Drugs, 2009
      • Figure 5.1, Leading Companies in the Antivirals Market: Market Shares (%), 2009
      • Figure 5.2, Top 15 Marketed Antiviral Drugs, Sales ($m), 2009
      • Figure 5.3, Top 15 Marketed Antiviral Drugs, Growth (%), 2009
      • Figure 5.4, Tamiflu Sales ($m), 2009-2015
      • Figure 5.5, Truvada Sales ($m), 2009-2015
      • Figure 5.6, Atripla Sales ($m), 2009-2015
      • Figure 5.7, Valtrex Sales ($m), 2009-2015
      • Figure 5.8, Pegasys Sales ($m), 2009-2015
      • Figure 5.9, Reyataz Sales ($m), 2009-2015
      • Figure 5.10, Kaletra Sales ($m), 2009-2015
      • Figure 5.11, Synagis Sales ($m), 2009-2015
      • Figure 5.12, Relenza Sales ($m), 2009-2015
      • Figure 5.13, Epzicom Sales ($m), 2009-2015
      • Figure 5.14, Pegintron Sales ($m), 2009-2015
      • Figure 5.15, Baraclude Sales ($m), 2009-2015
      • Figure 5.16, Prezista Sales ($m), 2009-2015
      • Figure 5.17, Combivir Sales ($m), 2009-2015
      • Figure 5.18, Isentress Sales ($m), 2009-2015
      • Figure 6.1, Antivirals in the Leading Pharmaceuticals Markets: Sales ($m), 2009
      • Figure 6.2, Antivirals in the Leading Pharmaceuticals Markets: Market Shares (%), 2009
      • Figure 6.3, Antivirals in the US Market: Sales ($m), 2009-2015
      • Figure 6.4, Antivirals in Other Leading Industrialised Countries: Sales ($m), 2010-2025
      • Figure 6.5, Antivirals in China and India: Sales ($m), 2009-2015
    • Companies Listed
      • Abbott
      • Alnylam Pharmaceuticals
      • American Association for the Study of Liver Diseases
      • Anadys
      • Ardea
      • AstraZeneca
      • Aurobindo
      • Beijing Mefuvir Medicinal Technology; Medivir
      • Benitec
      • Bill and Melinda Gates Foundation
      • BioChem Pharma
      • BioCryst Pharmaceuticals
      • Boehringer Ingelheim
      • Bristol-Myers Squibb
      • Cipla
      • Conatus
      • CytoDyn
      • Debiopharm
      • EMEA
      • Enzo Biochem
      • FDA
      • Gilead Sciences
      • GlaxoSmithKline
      • Heidelberg Pharma
      • Idenix
      • Innate Therapeutics
      • Intermune
      • International AIDS Vaccine Initiative (NIAID)
      • Johnson & Johnson
      • Médecins Sans Frontières
      • MedImmune
      • Merck & Co
      • Microbiocides (USA)
      • MIGENIX
      • Mitsubishi
      • Myriad
      • Novartis
      • PDL BioPharma
      • Pfizer
      • Pharmasset
      • Progenics
      • Roche
      • InterMune
      • Sanofi-Aventis
      • Schering-Plough
      • Shionogi
      • Shire
      • Tacere
      • Takeda
      • Tibotec-Virco
      • Tobira
      • Trellis Bioscience
      • Unitaid
      • US Department of Health and Human Services (HHS)
      • Valeant
      • Vertex
      • ViiV Healthcare
      • Virogen
      • ViroStatics
      • VIRxSYS
      • World Bank
      • World Health Organisation (WHO)